CS4 Bone Lesions in Hormone Refractory Prostate Cancer (HRPC)
نویسندگان
چکیده
منابع مشابه
Polyamine-reduced diet in metastatic hormone-refractory prostate cancer (HRPC) patients.
Polyamine (PA) deprivation is effective in prostate carcinoma models. We have assessed the observance by patients, tolerance and side effects of a PA-reduced diet (PRD) and intestinal decontamination (ID), in order to reduce PA dietary and intestinal bacterial pools, in metastatic, hormone-refractory prostate cancer (HRPC) patients. A total of 13 volunteers (mean age, 67+/-10 years) with metast...
متن کاملNew treatment strategies in the management of hormone refractory prostate cancer (HRPC): only chemotherapy?
Prostate cancer progression to androgen ablation refractory stage D3 corresponds to cancer cell escape from androgen withdrawal-induced apoptosis. In this development, enhancement of growth factor stimulation has an essential role in the upregulation of survival signals and constitutive proliferation [1]. The mainstay of treatment for metastatic prostate cancer is androgen deprivation. Unfortun...
متن کاملPrognostic indicators in hormone refractory prostate cancer.
Prognostic factors in hormone refractory prostate cancer currently are of limited use to clinicians. Although studies have identified several factors that predict for poor survival in patients, most are either retrospective, or nonrandomized. Therefore, large prospective, randomized trials are needed to validate the significance of these factors. In addition, these indicators are largely descri...
متن کاملTherapeutic approach to hormone-refractory prostate cancer.
Over 60 years ago, Huggins and Hodges discovered androgen deprivation as an effective first-line therapy for metastatic prostate cancer. This leads to significant cancer control but in almost all men prostate cancer ultimately progresses to a hormone-refractory (HRPC) state resulting in significant morbidity and eventual death. In 2004, two landmark studies using docetaxel based chemotherapy de...
متن کاملManagement of Hormone-Sensitive and Hormone-Refractory Metastatic Prostate Cancer.
BACKGROUND: Prostate cancer is a significant health problem in the United States and is the focus of increasing attention in our society. With the aging of the US population, it is likely that prostate cancer will continue to grow in importance. The options for systemic therapy of metastatic prostate cancer should be familiar to physicians, including nonspecialists, whose patients seek their ad...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Japanese Journal of Urology
سال: 2006
ISSN: 0021-5287,1884-7110
DOI: 10.5980/jpnjurol.97.118